Dyslipidemia correction with atorvastatin in patients with coronary heart disease and arterial hypertension

Dyslipidemia correction with atorvastatin in patients with coronary heart disease and arterial hypertension

Aim. To assess atorvastatin lipid-lowering effect and tolerability at the initial stage of lipid-lowering treatment. Material and methods. The study included 47 patients (14 women, 33 men; mean age 55,6±11,6 years). Inclusion criteria were: verified coronary heart disease, CHD (stable effort angina,...

Full description

Saved in:

Bibliographic Details
Main Authors:	N. B. Amirov, M. V. Potapova, F. I. Ishkineev, G. V. Tukhvatullina, N. G. Efimova, L. F. Mingazutdinova
Format:	Article
Language:	Russian
Published:	«SILICEA-POLIGRAF» LLC 1970-01-01
Series:	Кардиоваскулярная терапия и профилактика
Subjects:	dyslipidemia coronary heart disease lipid-lowering therapy atorvastatin
Online Access:	https://cardiovascular.elpub.ru/jour/article/view/1480
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Atorvastatin effectiveness in dyslipidemia correction among coronary heart disease and arterial hypertension patients with high risk of cardiovascular complications
by: E. V. Minakov, et al.
Published: (2007-10-01)

EFFECTS OF ATORVASTATIN IN PATIENTS WITH RHEUMATOID ARTHRITIS AND DYSLIPIDEMIA
by: N. M. Nikitina, et al.
Published: (2014-07-01)

Effectiveness, safety, and endothelial function effects of atorvastatin lipid-lowering therapy in coronary heart disease patients undergoing percutaneous coronary intervention
by: M. P. Mal’gina, et al.
Published: (2007-06-01)

Efficacy and Safety of the Fixed-Dose Combination of Atorvastatin/Fenofibrate Versus Atorvastatin on the Lipid Profile of Patients with Type 2 Diabetes and Dyslipidemia
by: Francisco G. Padilla-Padilla, et al.
Published: (2025-05-01)

Randomized «FARVATER» study. Atorvastatin (10 and 20 mg/d) in treating patients with coronary heart disease and dyslipidemia: effects on lipids, C-reactive protein and fibrinogen levels
by: A. V. Susekov, et al.
Published: (2006-12-01)

Randomized study FARVATER: Part II. Atorvastatin effects on endothelial function, vascular wall distensibility and stiffness
by: A. V. Susekov, et al.
Published: (2007-06-01)

STATINS AND PERCUTANEOUS CORONARY INTERVENTION. FOCUS ON THE ATORVASTATIN
by: N. G. Gogolashvili
Published: (2015-09-01)

Associations Between the Polymorphisms in the Coding Sequence of SLCO1B1 and Blood Lipid Levels Before and After Treatment by Atorvastatin in the Chinese Han Adults with Dyslipidemia
by: Chen C, et al.
Published: (2024-12-01)

USING A COMBINATION OF PERINDOPRIL, INDAPAMIDE AND ROSUVASTATIN IN THE TREATMENT OF PATIENTS WITH HYPERTENSION AND DYSLIPIDEMIA
by: O. M. Drapkina, et al.
Published: (2017-09-01)

Long-term low-dose atorvastatin therapy and prevention of macroangiopathy complications in elderly patients with Type 2 diabetes mellitus
by: G. A. Batrak, et al.
Published: (2010-06-01)

The Effectiveness and Safety of Fenofibrate and Saroglitazar in the Treatment of Diabetic Dyslipidemia
by: Bakhtawar Farooq, et al.
Published: (2024-05-01)

RECENT ADVANCES IN THE APPLICATION OF HIGH DOSES OF ATORVASTATIN IN PATIENTS WITH CORONARY HEART DISEASE
by: M. V. Ezhov
Published: (2016-01-01)

Aggressive statin therapy in acute coronary syndrome: therapeutic potential of atorvastatin in the daily dose of 80 mg
by: A. N. Britov
Published: (2009-12-01)

Possibilities of atorvastatin loading dose using for the prevention of perioperative myocardial damage in patients with stable coronary artery disease
by: A. S. Ragozina, et al.
Published: (2019-11-01)

Dose-dependent effects of atorvastatin in the hospitalisation period of myocardial infarction
by: O. L. Barbarash, et al.
Published: (2013-06-01)

Anti-inflammatory effects of low- and high-dose atorvastatin therapy in patients with coronary heart disease and rheumatoid arthritis
by: V. S. Tutunov, et al.
Published: (2008-10-01)

SPECIFICS OF LIPID METABOLISM AND ATORVASTATIN EFFICACY IN TYPE 2 DIABETES WITH CARRIAGE OF VARIOUS POLYMORPHISMS OF CHOLESTEROL ETHER CARRYING PROTEIN TaqIB GENE
by: M. V. Kim, et al.
Published: (2015-10-01)

Short Term Comparison Between Safety and Efficacy of Rosuvastatin 40 mg and Atorvastatin 80 mg in Patients with Acute Coronary Syndrome
by: Sh. A. Mostafa, et al.
Published: (2018-11-01)

Lipid and pleiotropic effects of atorvastatin in patients with high cardiovascular risk
by: R. S. Karpov, et al.
Published: (2009-08-01)

ACUTE ATORVASTATIN RECAPTURE THERAPY IN CORONARY ARTERY BYPASS GRAFTING
by: A. V. Panov, et al.
Published: (2017-07-01)

Lipid and pleiotropic effects of atorvastatin in patients with acute coronary syndrome
by: A. A. Yalymov, et al.
Published: (1970-01-01)

Comparison of ezetimibe and atorvastatin versus atorvastatin alone on short-term major adverse cardiac events after percutaneous coronary intervention, a double-blind placebo-controlled randomized clinical trial
by: Hossein Farshidi, et al.
Published: (2025-03-01)

Statinotherapy – the paradigm of prevention and treatment of atherosclerotic pathology (focus on atorvastatin)
by: R. G. Oganov, et al.
Published: (2006-12-01)

Atherogenic dyslipidemia and insulin resistance associated with nonalcohol hepatic steatosis: comparison, contrast, and differentiated therapy
by: L. B. Lazebnik, et al.
Published: (2009-06-01)

Effects of Trimetazidine Combined with Atorvastatin on Cardiac Function in Patients with Stable Angina Pectoris of Coronary Heart Disease
by: Zhang N, et al.
Published: (2025-04-01)

Potential of combination therapy in patients with hypertension and dyslipidemia
by: T. V. Gorokhova, et al.
Published: (2022-08-01)

Eurasian Association of Cardiology (EAC)/ Russian National Atherosclerosis Society (RNAS) Guidelines for the diagnosis and correction of dyslipidemia for the prevention and treatment of atherosclerosis (2025)
by: M. V. Ezhov, et al.
Published: (2025-06-01)

Dyslipidemia in Psoriasis: A Case - Controlled Study
by: Monique Kafle, et al.
Published: (2021-10-01)

Dyslipidemia in Psoriasis: A Case - Controlled Study
by: Monique Kafle, et al.
Published: (2021-10-01)

The impact of atorvastatin on hemorheology and inflammatory cytokines of patients with hypertensive nephropathy
by: WANG Li, et al.
Published: (2017-01-01)

ATORVASTATIN — 20 YEARS IN THE STRUGGLE FOR LIFE
by: N. G. Gogolashvili
Published: (2018-03-01)

ATORVASTATIN IN ACUTE AND CHRONIC KINDS OF ISCHEMIC HEART DISEASE
by: V. E. Oleynikov, et al.
Published: (2015-11-01)

Efficacy of atorvastatin therapy in prevention of postoperative atrial fibrillation in patients with ischemic heart disease
by: O. A. Rubanenko
Published: (2015-11-01)

Nephroprotective effect of atorvastatin at a dose of 80 mg in patients with ST-segment elevation myocardial infarction with an invasive treatment strategy
by: A. D. Gavrilko, et al.
Published: (2023-11-01)

Analyzing lipid profiles and dyslipidemia prevalence in hypertensive patients: a cross-sectional study from primary community health institutions
by: Wenxin Wang, et al.
Published: (2024-12-01)

EFFICIENCY AND SAFETY ASSESSMENT OF GENERIC ATORVASTATINE IN PATIENTS WITH HYPERLIPIDEMIA
by: J. E. Semyonova, et al.
Published: (2015-12-01)

Associations of polyphenolic compounds consumption and the risk of dyslipidemia in the Siberian population
by: T. I. Batluk, et al.
Published: (2020-06-01)

THE ROLE OF LIPOTROPIC THERAPY IN PATIENTS WITH CHRONIC ISCHEMIC HEART DISEASE BEFORE AND AFTER CORONARY REVASCULARIZATION
by: R. N. Adzhiev, et al.
Published: (2015-09-01)

EFFICACY AND SAFETY OF THERAPY WITH ATORVASTATIN IN HIGH DOSES
by: A. N. Meshkov
Published: (2016-01-01)

Lipid-lowering effectiveness of a Russian generic of atorvastatin in patients with various hyperlipidaemia phenotypes
by: P. P. Malyshev, et al.
Published: (2009-12-01)